Lupus Erythematosus News and Research

RSS

Pre-existing anti-IFN autoantibodies may worsen COVID-19 in lupus patients

“Our observations suggest that the presence of these autoantibodies may predispose SLE patients to infection with SARS-CoV-2 with a more severe presentation and represent an additional risk factor in this patient population,” write Sarthak Gupta and colleagues from the National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland.

5 Nov 2020

Lung biomarkers may predict severe COVID-19

Two University of New Mexico researchers postulate certain specific biomarkers' relevance in predicting the potential for progression to severe COVID-19 in a paper published on the preprint server bioRxiv*

27 Oct 2020

Exuberant activation of immune cells in severe COVID-19 resembles lupus

In severe cases of COVID-19, Emory researchers have been observing an exuberant activation of immune cells, resembling acute flares of systemic lupus erythematosus (SLE), an autoimmune disease.

9 Oct 2020

Auto-antibodies may explain why some people develop severe COVID-19

Now, a new study by an international team of health experts shows that some life-threatening cases of COVID-19 can be traced to specific weak spots in the patients' immune system.

28 Sep 2020

Targeted treatment for systemic lupus erythematosus

A team of researchers from Charité - Universitätsmedizin Berlin and the Deutsches Rheuma-Forschungszentrum Berlin, a Leibniz Institute, have successfully treated two patients with the autoimmune disease systemic lupus erythematosus.

22 Sep 2020

Memory B cells indicate durable immunity in COVID-19

Now a new study by researchers at SUNY Upstate Medical University and published recently on the preprint server medRxiv in September 2020 shows that memory B cells are upregulated in convalescent COVID-19 patients, correlating with a better immune response and shorter symptom duration.

8 Sep 2020

Hydroxychloroquine is not a possible defense against COVID-19, study shows

Researchers at Case Western Reserve University have added to the growing body of understanding about how hydroxychloroquine (HCQ) is not a possible defense against COVID-19.

17 Aug 2020

New method helps pinpoint new potential therapeutic targets for lupus

A team of researchers from Children's Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders.

8 Jul 2020

Research sheds light on mysterious COVID-19 related hyperinflammatory shock in children

The ongoing COVID-19 pandemic has cost hundreds of thousands of human lives, besides more than 11 million cases. Caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease was initially thought to be more severe in the elderly and those with pre-existing medical conditions. However, it started to manifest in children after the peak of the first wave.

7 Jul 2020

Hydroxychloroquine suppresses 'trained immunity'

A new study published on the preprint server medRxiv in June 2020 shows that the drug hydroxychloroquine (HCQ) suppresses a form of immunity called ‘trained immunity,’ with repercussions for its potential use to treat COVID-19.

11 Jun 2020

Researchers develop new method to measure hydroxychloroquine levels in SLE patients

Researchers at Uppsala University and Uppsala University Hospital have developed a new method to measure levels of the medication hydroxychloroquine in patients with rheumatic disease systemic lupus erythematosus (SLE).

1 Jun 2020

Study examines changes in prescription patterns during COVID-19 pandemic

A new study by investigators from Brigham and Women's Hospital examines changes in prescription patterns in the United States during the COVID-19 pandemic.

29 May 2020

Gene variants can increase risk of schizophrenia, shows study

Variants in a gene of the human immune system cause men and women to have different vulnerabilities to the autoimmune diseases lupus and Sjögren's syndrome, according to findings published in the journal Nature.

19 May 2020

Study provides genetic explanation behind the sex bias observed in certain diseases

Some diseases exhibit a clear sex bias, occurring more often, hitting harder or eliciting different symptoms in men or women.

12 May 2020

Hydroxychloroquine is not effective against COVID-19, extensive U.S. study shows

Over the past few months, doctors resorted to repurposing medicines that have already been approved for other diseases to treat coronavirus patients. One drug that was widely used in the pandemic, hydroxychloroquine, has been found to be ineffective in treating the viral infection.

11 May 2020

Microbiome controls the fitness of our immune system

Working alongside colleagues in Mainz, Bern, Hannover and Bonn, researchers from Charité - Universitätsmedizin Berlin, the Berlin Institute of Health and the German Rheumatism Research Center Berlin were able to show how the microbiome helps to render the immune system capable of responding to pathogens.

11 May 2020

Study finds race-specific lupus nephritis biomarkers for early diagnosis, treatment

University of Houston Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, Chandra Mohan, and his team have discovered a difference in urinary biomarker proteins of lupus nephritis in patients according to race.

6 May 2020

COVID-19 progression linked to B cell activation

The disease course of COVID-19 is diverse, ranging from asymptomatic to fatal respiratory failure. Scientists have been working to uncover the immunological reasons behind this heterogeneity. A recent study on B cells, published on the preprint server medRxiv in April 2020, shows that extrafollicular B cells could be a marker of severe infection in the early stages, predicting the need for earlier immunomodulatory therapy.

4 May 2020

How toxic are chloroquine and hydroxychloroquine to cells?

The spread of the pandemic disease COVID-19 caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has now reached almost every country of the world, with over 3.11 million cases and over 217,000 deaths as of April 29, 2020.

29 Apr 2020

Is the confidence in hydroxychloroquine for the management of COVID-19 justified?

A new review paper published in the preprint open-access journal medRxiv in April 2020 reports that there is not enough evidence to justify the widespread use of the drug hydroxychloroquine (HCQ) in the treatment or prophylaxis of the current COVID-19 illness.

23 Apr 2020